Advancing peptides for the treatment of rare endocrine and metabolic disorders

We are building on our team's established expertise in therapeutic peptides to deliver life-changing treatments to patients suffering from rare endocrine and metabolic diseases.

PROGRAMS

AZP-3601

Our lead clinical candidate is a therapeutic peptide in development as a potential treatment for hypoparathyroidism, a rare endocrine disorder.

AZP-3813

AZP-3813 is a highly potent, macrocyclic peptide growth hormone (GH) receptor antagonist in development as a potential treatment for acromegaly.

AZP-3813 Acromegal

AZP-3404

AZP-3404

AZP-3404 is a first-in-class therapeutic peptide that may restore fat and glucose metabolism in the body.

LEADERSHIP

Our management team has the collective and proven expertise necessary to advance its portfolio of therapeutic peptides in the clinic.

Press Releases & Recent News

Amolyt Pharma to Present Phase 1 Clinical Trial Data for Lead Product Candidate AZP-3601 at the American Society for Bone and Mineral Research 2021 Annual Meeting

Amolyt Pharma to Present Phase 1 Clinical Trial Data for Lead Product Candidate AZP-3601 at the American Society for Bone …

Read More →
Download a PDF: EN or FR

Amolyt Pharma Announces $80 Million Series B Financing led by Sectoral Asset Management and Andera Partners

Download a PDF copy of this press release: EN FR Funds to be used to continue clinical development of AZP-3601 …

Read More →
Download a PDF: EN or FR

Join Our Team

We are always looking for talented and driven individuals to join our diverse and collaborative team to help us achieve our mission.

Contact Us

We welcome open and continuous dialogue with all interested parties, including patients, healthcare providers, potential partners and investors.

Scroll to Top